- Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
- Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
- Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
More ▼
Key statistics
As of last trade Vera Therapeutics Inc (VERA:NMQ) traded at 36.88, -27.37% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.31 |
---|---|
High | 39.39 |
Low | 36.55 |
Bid | 36.79 |
Offer | 36.88 |
Previous close | 37.08 |
Average volume | 568.90k |
---|---|
Shares outstanding | 54.70m |
Free float | 50.37m |
P/E (TTM) | -- |
Market cap | 2.03bn USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of May 24 2024 20:11 BST.
More ▼